Celldex Therapeutics Inc., a biotechnology company specializing in immunological applications for the prevention and treatment of autoimmune diseases, cancer, cardiovascular issues, inflammation, infectious diseases, and organ transplant rejection, has seen a significant update in its ownership structure.

According to a Schedule 13G/A amendment filed with the Securities and Exchange Commission (SEC) on November 16, 2026, Wellington Management Group and its affiliated entities collectively hold approximately 13.9% of the common stock of Celldex Therapeutics Inc. The filing provides specific details regarding share ownership, as well as voting and disposing rights, and includes the necessary compliance certifications.

The submission of this amendment is a regulatory requirement for entities holding more than five percent of a company’s shares. The filing indicates that there has been no change in control or significant disposition of shares, reflecting the sustained investment position maintained by Wellington Management Group in the company.

Celldex Therapeutics Inc. is listed on the Nasdaq stock exchange. As of the market close on November 16, 2026, the company’s stock price was 28.04 USD. The company maintains a market capitalization of 2.25 billion USD.